Series A · Medtech & Devices · Paris, France · Founded 2014 · 11–50 employees
Damae Medical develops the deepLive™ medical device that revolutionizes skin cancer diagnosis through non-invasive optical biopsies using proprietary LC-OCT technology. The device provides 3D images of skin layers at cellular level, eliminating the need for traditional biopsies and reducing diagnosis time from 15 days to immediate results. Founded in 2014 from research at CNRS, the company has raised over €7 million and is CE marked for commercial use in Europe. Their technology is used in over 40 reference centers across 11 countries, with significant traction in France, Germany, and Italy, and is backed by leading medical publications and clinical validation.